{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T17:50:44Z","timestamp":1785261044572,"version":"3.55.0"},"reference-count":32,"publisher":"Japan Atherosclerosis Society","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAT","J Atheroscler Thromb"],"published-print":{"date-parts":[[2021,10,1]]},"DOI":"10.5551\/jat.60343","type":"journal-article","created":{"date-parts":[[2020,12,17]],"date-time":"2020-12-17T22:07:27Z","timestamp":1608242847000},"page":"1083-1094","source":"Crossref","is-referenced-by-count":22,"title":["CAVI-Lowering Effect of Pitavastatin May Be Involved in the Prevention of Cardiovascular Disease: Subgroup Analysis of the TOHO-LIP"],"prefix":"10.5551","volume":"28","author":[{"given":"Atsuhito","family":"Saiki","sequence":"first","affiliation":[{"name":"Center of Diabetes, Endocrine and Metabolism, Toho University Sakura Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhiro","family":"Watanabe","sequence":"additional","affiliation":[{"name":"Center of Diabetes, Endocrine and Metabolism, Toho University Sakura Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Yamaguchi","sequence":"additional","affiliation":[{"name":"Center of Diabetes, Endocrine and Metabolism, Toho University Sakura Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Ohira","sequence":"additional","affiliation":[{"name":"Center of Diabetes, Endocrine and Metabolism, Toho University Sakura Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daiji","family":"Nagayama","sequence":"additional","affiliation":[{"name":"Center of Diabetes, Endocrine and Metabolism, Toho University Sakura Medical Center"},{"name":"Nagayama Clinic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoko","family":"Sato","sequence":"additional","affiliation":[{"name":"Pharmaceutical Unit, Toho University Sakura Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mizuho","family":"Kanayama","sequence":"additional","affiliation":[{"name":"Pharmaceutical Unit, Toho University Sakura Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mao","family":"Takahashi","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Medicine (Sakura), Department of Internal Medicine, Faculty of Medicine, Toho University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhiro","family":"Shimizu","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Medicine (Sakura), Department of Internal Medicine, Faculty of Medicine, Toho University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masao","family":"Moroi","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Medicine (Ohashi), Department of Internal Medicine, Faculty of Medicine, Toho University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoh","family":"Miyashita","sequence":"additional","affiliation":[{"name":"Medical Correction Center in East Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kohji","family":"Shirai","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Mihama Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ichiro","family":"Tatsuno","sequence":"additional","affiliation":[{"name":"Center of Diabetes, Endocrine and Metabolism, Toho University Sakura Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3489","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) Scandinavian Simvastatin Survival Study Group: Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet, 1994; 344: 1383-1389","DOI":"10.1016\/S0140-6736(94)90566-5"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, McKillop JH, Packard CJ: Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med, 1995; 333: 1301-1307","DOI":"10.1056\/NEJM199511163332001"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ, Thomason MJ, Mackness MI, Charlton-Menys V, Fuller JH; CARDS investigators: Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet, 2004; 364: 685-696","DOI":"10.1016\/S0140-6736(04)16895-5"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) Sever PS, Dahl\u00f6f B, Poulter NR, Wedel H, Beevers G, Caulfield M, Collins R, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, O\u2019Brien E, Ostergren J; ASCOT investigators: Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet, 2003; 361: 1149-1158","DOI":"10.1016\/S0140-6736(03)12948-0"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) LaRosa JC, Grundy SM, Waters DD, Shear C, Barter P, Fruchart J-C, Gotto AM, Greten H, Kastelein JJP, Shepherd J, Wenger NK, for the Treating to New Targets (TNT) Investigators: Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med, 2005; 352: 1425-1435","DOI":"10.1056\/NEJMoa050461"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6) Fujino H, Yamada I, Shimada S, Nagao T, Yoneda M: Metabolic fate of pitavastatin (NK-104), a new inhibitor of 3-hydroxy-3-methyl-glutaryl coenzyme A reductase. Effects on drug-metabolizing systems in rats and humans. Arzneimittelforschung, 2002; 52: 745-753","DOI":"10.1055\/s-0031-1299961"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) Yokote K, Bujo H, Hanaoka H, Shinomiya M, Mikami K, Miyashita Y, Nishikawa T, Kodama T, Tada N, Saito Y: Multicenter collaborative randomized parallel group comparative study of pitavastatin and atorvastatin in Japanese hypercholesterolemic patients: collaborative study on hypercholesterolemia drug intervention and their benefits for atherosclerosis prevention (CHIBA study). Atherosclerosis, 2008; 201: 345-352","DOI":"10.1016\/j.atherosclerosis.2008.02.008"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) Gumprecht J, Gosho M, Budinski D, Hounslow N: Comparative long-term efficacy and tolerability of pitavastatin 4mg and atorvastatin 20-40 mg in patients with type 2 diabetes mellitus and combined (mixed) dyslipidaemia. Diabetes Obes Metab, 2011; 13: 1047-1055","DOI":"10.1111\/j.1463-1326.2011.01477.x"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) Mita T, Nakayama S, Abe H, Dosho M, Iida M, Hirose T, Kawamoro R, Watada H: Comparison of effects of pitavastatin and atorvastatin on glucose metabolism in type 2 diabetic patients with hypercholesterolemia. J Diabetes Investig, 2013; 4: 297-303","DOI":"10.1111\/jdi.12032"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) Choi JY, Choi CU, Hwang SY, Kim HS, Jeong MH, KAMIR-NIH Investigators: Effect of pitavastatin compared with atorvastatin and rosuvastatin on new-onset diabetes mellitus in patients with acute myocardial infarction. Am J Cardiol, 2018; 122: 922-928","DOI":"10.1016\/j.amjcard.2018.06.017"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11) Sasaki J, Ikeda Y, Kuribayashi T, Tadanobu K, Keizou K, Sadatoshi B, Kyosuke Y, Masato A, Syozou K, Tetsunori S, Takatoshi O, Suminori K: A 52-week, randomized, open-label, parallel group comparison of the tolerability and effects of pitavastatin and atorvastatin on high-density lipoprotein cholesterol levels and glucose metabolism in Japanese patients with elevated levels of low-density lipoprotein cholesterol and glucose intolerance. Clin Ther, 2008; 30: 1089-1101","DOI":"10.1016\/j.clinthera.2008.05.017"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12) Sakabe K, Fukuda N, Fukuda Y, Wakayama K, Nada T, Morishita S, Shinohara H, Tamura Y: Comparisons of short- and intermediate-term effects of pitavastatin versus atorvastatin on lipid profiles, fibrinolytic parameter, and endothelial function. Int J Cardiol, 2008; 125: 136-138","DOI":"10.1016\/j.ijcard.2007.01.040"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13) Moroi M, Nagayama D, Hara F, Saiki A, Shimizu K, Takahashi M, Sato N, Shiba T, Sugimoto H, Fujioka T, Chiba T, Nishizawa K, Usui S, Iwasaki Y, Tatsuno I, Sugi K, Yamasaki J, Yamamura S, Shirai K: Outcome of pitavastatin versus atorvastatin therapy in patients with hypercholesterolemia at high risk for atherosclerotic cardiovascular disease. Int J Cardiol, 2020; 305: 139-146","DOI":"10.1016\/j.ijcard.2020.01.006"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14) Hayashi K, Yamamoto T, Takahara A, Shirai K: Clinical assessment of arterial stiffness with cardio-ankle vascular index: theory and applications. J Hypertens, 2015; 33: 1742-1757","DOI":"10.1097\/HJH.0000000000000651"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15) Saiki A, Ohira M, Yamaguchi T, Nagayama D, Shimizu N, Shirai K, Tatsuno I: New horizons of arterial stiffness developed using cardio-ankle vascular index (CAVI). J Atheroscler Thromb, 2020; 27: 732-748","DOI":"10.5551\/jat.RV17043"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16) Shirai K, Song M, Suzuki J, Kurosu T, Oyama T, Nagayama D, Miyashita Y, Yamamura S, Takahashi M: Contradictory effects of b1- and a1-aderenergic receptor blockers on cardio-ankle vascular stiffness index (CAVI): the independency of CAVI from blood pressure. J Atheroscler Thromb, 2011; 18: 49-55","DOI":"10.5551\/jat.3582"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17) Nagayama D, Watanabe Y, Saiki A, Shirai K, Tatsuno I: Lipid parameters are independently associated with cardio-ankle vascular index (CAVI) in healthy Japanese subjects. J Atheroscler Thromb, 2018; 25: 621-633","DOI":"10.5551\/jat.42291"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18) Miyashita Y, Endo K, Saiki A, Ban N, Yamaguchi T, Kawana H, Nagayama D, Ohira M, Oyama T, Shirai K: Effects of pitavastatin, a 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor, on cardio-ankle vascular index in type 2 diabetic patients. J Atheroscler Thromb, 2009; 16: 539-545","DOI":"10.5551\/jat.281"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19) Sato Y, Nagayama D, Saiki A, Watanabe R, Watanabe Y, Imamura H, Yamaguchi T, Ban N, Kawana H, Nagumo A, Ohira M, Endo K, Kurosu T, Tomaru T, Shirai K, Tatsuno I: Cardio-ankle vascular index is independently associated with future cardiovascular events in outpatients with metabolic disorders. J Atheroscler Thromb, 2016; 23: 596-605","DOI":"10.5551\/jat.31385"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20) Hiro T, Kimura T, Morimoto T, Miyauchi K, Nakagawa Y, Yamagishi M, Ozaki Y, Kimura K, Saito S, Yamaguchi T, Daida H, Matsuzaki M, JAPAN-ACS Investigators: Effect of intensive statin therapy on regression of coronary atherosclerosis in patients with acute coronary syndrome: a multicenter randomized trial evaluated by volumetric intravascular ultrasound using pitavastatin versus atorvastatin (JAPAN-ACS [Japan assessment of pitavastatin and atorvastatin in acute coronary syndrome] study). J Am Coll Cardiol, 2009; 54: 293-302","DOI":"10.1161\/circ.118.suppl_18.S_657-c"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21) Shirai K, Utino J, Otsuka K, Takata M: A novel blood pressure-independent arterial wall stiffness parameter; cardio-ankle vascular index (CAVI). J Atheroscler Thromb, 2006; 13: 101-107","DOI":"10.5551\/jat.13.101"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22) Namekata T, Suzuki K, Ishizuka N, Shirai K: Establishing baseline criteria of cardio-ankle vascular index as a new indicator of arteriosclerosis: a cross-sectional study. BMC Cardiovasc Disord, 2011; 11: 51","DOI":"10.1186\/1471-2261-11-51"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23) Yamaguchi T, Shirai K, Nagayama D, Nakamura S, Oka R, Tanaka S, Watanabe Y, Imamura H, Sato Y, Kawana H, Ohira M, Saiki A, Shimizu N, Tatsuno I: Bezafibrate ameliorates arterial stiffness assessed by cardio-ankle vascular index in hypertriglyceridemic patients with type 2 diabetes mellitus. J Atheroscler Thromb, 2019; 26: 659-669","DOI":"10.5551\/jat.45799"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24) Dobsak P, Soska V, Sochor O, Jarkovsky J, Novakova M, Homolka M, Soucek M, Palanova P, Lopez-Jimenez F, Shirai K: Increased cardio-ankle vascular index in hyperlipidemic patients without diabetes or hypertension. J Atheroscler Thromb, 2015; 22: 272-283","DOI":"10.5551\/jat.24851"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25) Soska V, Dobsak P, Dusek L, Shirai K, Jarkovsky J, Novakova M, Brhel P, Stastna J, Fajkusova L, Freiberger T, Yambe T: Cardio-ankle vascular index in heterozygous familial hypercholesterolemia. J Atheroscler Thromb, 2012; 19: 453-461","DOI":"10.5551\/jat.9639"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26) Suzuki M, Takahashi M, Iizuka T, Terada H, Noike H, Shirai K: Frequency of coronary artery stenosis in patients with asymptomatic familial hypercholesterolemia and its association with carotid intimal thickness and cardio-ankle vascular index. Research Reports in Clinical Cardiology, 2016; 7; 83-90","DOI":"10.2147\/RRCC.S101805"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27) Pavlovska I, Kunzova S, Jakubik J, Hruskova J, Skladana M, Rivas-Serna IM, Medina-Inojosa JR, Lopez-Jimenez F, Vysoky R, Geda YE, Stokin GB, Gonz\u00e1lez-Rivas JP: Associations between high triglycerides and arterial stiffness in a population-based sample: Kardiovize Brno 2030 study. Lipids Health Dis, 2020; 19: 170","DOI":"10.1186\/s12944-020-01345-0"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28) Saiki A, Murano T, Watanabe F, Oyama T, Miyashita Y, Shirai K: Pitavastatin enhanced lipoprotein lipase expression in 3T3-L1 preadipocytes. J Atheroscler Thromb, 2005; 12: 163-168","DOI":"10.5551\/jat.12.163"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29) Nagashima H, Kasanuki H: Therapeutic value of statins for vascular remodeling. Curr Vasc Pharmacol, 2003; 1: 273-279","DOI":"10.2174\/1570161033476592"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30) Teramoto T, Shimano H, Yokote K, Urashima M: Effects of pitavastatin (LIVALO Tablet) on high density lipoprotein cholesterol (HDL-C) in hypercholesterolemia. J Atheroscler Thromb, 2009; 16: 654-661","DOI":"10.5551\/jat.1719"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31) Taguchi I, Iimuro S, Iwata H, Takashima H, Abe M, Amiya E, Ogawa T, Ozaki Y, Sakuma I, Nakagawa Y, Hibi K, Hiro T, Fukumoto Y, Hokimoto S, Miyauchi K, Yamazaki T, Ito H, Otsuji Y, Kimura K, Takahashi J, Hirayama A, Yokoi H, Kitagawa K, Urabe T, Okada Y, Terayama Y, Toyoda K, Nagao T, Matsumoto M, Ohashi Y, Kaneko T, Fujita R, Ohtsu H, Ogawa H, Daida H, Shimokawa H, Saito Y, Kimura T, Inoue T, Matsuzaki M, Nagai R: High-Dose Versus Low-Dose Pitavastatin in Japanese Patients With Stable Coronary Artery Disease (REAL-CAD): A Randomized Superiority Trial. Circulation, 2018; 137: 1997-2009","DOI":"10.1161\/CIRCULATIONAHA.117.032615"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32) Kinoshita M, Yokote K, Arai H, Iida M, Ishigaki Y, Ishibashi S, Umemoto S, Egusa G, Ohmura H, Okamura T, Kihara S, Koba S, Saito I, Shoji T, Daida H, Tsukamoto K, Deguchi J, Dohi S, Dobashi K, Hamaguchi H, Hara M, Hiro T, Biro S, Fujioka Y, Maruyama C, Miyamoto, Y, Murakami Y, Yokode M, Yoshida H, Rakugi H, Wakatsuki A, Yamashita S; Committee for Epidemiology and Clinical Management of Atherosclerosis: Japan Atherosclerosis Society (JAS) Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases 2017. J Atheroscler Thromb, 2018; 25: 846-984","DOI":"10.5551\/jat.GL2017"}],"container-title":["Journal of Atherosclerosis and Thrombosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jat\/28\/10\/28_60343\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,8]],"date-time":"2024-05-08T04:39:12Z","timestamp":1715143152000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jat\/28\/10\/28_60343\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,1]]},"references-count":32,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.5551\/jat.60343","relation":{},"ISSN":["1340-3478","1880-3873"],"issn-type":[{"value":"1340-3478","type":"print"},{"value":"1880-3873","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,1]]},"article-number":"60343"}}